Virus-drug resistance: thymidine kinase-deficient (TK-) mutants of herpes simplex virus. Therapeutic approaches.
de Clercq
E
E
D000212:Acyclovir / Q000494:pharmacology / Q000627:therapeutic use; D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D006561:Herpes Simplex / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D018139:Simplexvirus / Q000187:drug effects* / Q000201:enzymology / Q000302:isolation & purification; D013937:Thymidine Kinase / Q000172:deficiency / Q000235:genetics; D014764:Viral Proteins / Q000172:deficiency / Q000235:genetics
D000998:Antiviral Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D014764:Viral Proteins; C050127:9-(S)-(3-hydroxy-2-(phosphonomethoxy)propyl)adenine; D013937:Thymidine Kinase; D000225:Adenine; D000212:Acyclovir